


13534 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

should be such that doctors will be compelled to protect themselves from a later malpractice suit by obtaining truly informed consent from their patients, and by demonstrating in the patient's record that the patient's symptoms could not be controlled by diet and/or insulin." (Nelson Hearings, p. 10999).

Faced with such a warning label, most doctors, in the interests of their patients (and themselves) would make a much greater effort to avoid use of these dangerous drugs.

In summary, it is long past the time for FDA to have issued a strong warning label for these drugs. Any further delay should result in sanctions against all FDA officials who have been responsible.

Sincerely,



Sidney M. Wolfe, M.D.



Anita Johnson, esq.